Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Identifieur interne : 002025 ( Main/Exploration ); précédent : 002024; suivant : 002026Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Auteurs : Sherene Loi [Australie] ; Urania Dafni [Grèce] ; Dimitris Karlis [Grèce] ; Varvara Polydoropoulou [Grèce] ; Brandon M. Young [États-Unis] ; Scooter Willis [États-Unis] ; Bradley Long [États-Unis] ; Evandro De Azambuja [Belgique] ; Christos Sotiriou [Belgique] ; Giuseppe Viale [Italie] ; Josef Rüschoff [Allemagne] ; Martine J. Piccart [Belgique] ; Mitch Dowsett [Royaume-Uni] ; Stefan Michiels [France] ; Brian Leyland-Jones [États-Unis]Source :
- JAMA oncology [ 2374-2445 ] ; 2016.
Descripteurs français
- KwdFr :
- ARN messager (métabolisme), Adulte, Adulte d'âge moyen, Analyse multivariée, Antinéoplasiques (usage thérapeutique), Carcinomes (métabolisme), Carcinomes (traitement médicamenteux), Essais contrôlés randomisés comme sujet, Femelle, Humains, Immunohistochimie, Modèles de hasards proportionnels, Pronostic, Récepteur ErbB-2 (génétique), Récepteur ErbB-2 (métabolisme), Récepteur alpha des oestrogènes (génétique), Récepteur alpha des oestrogènes (métabolisme), Survie sans rechute, Technique FISH, Traitement médicamenteux adjuvant, Trastuzumab (usage thérapeutique), Tumeurs du sein (métabolisme), Tumeurs du sein (traitement médicamenteux).
- MESH :
- génétique : Récepteur ErbB-2, Récepteur alpha des oestrogènes.
- métabolisme : ARN messager, Carcinomes, Récepteur ErbB-2, Récepteur alpha des oestrogènes, Tumeurs du sein.
- traitement médicamenteux : Carcinomes, Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques, Trastuzumab.
- Adulte, Adulte d'âge moyen, Analyse multivariée, Essais contrôlés randomisés comme sujet, Femelle, Humains, Immunohistochimie, Modèles de hasards proportionnels, Pronostic, Survie sans rechute, Technique FISH, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- Adult, Antineoplastic Agents (therapeutic use), Breast Neoplasms (drug therapy), Breast Neoplasms (metabolism), Carcinoma (drug therapy), Carcinoma (metabolism), Chemotherapy, Adjuvant, Disease-Free Survival, Estrogen Receptor alpha (genetics), Estrogen Receptor alpha (metabolism), Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, RNA, Messenger (metabolism), Randomized Controlled Trials as Topic, Receptor, ErbB-2 (genetics), Receptor, ErbB-2 (metabolism), Trastuzumab (therapeutic use).
- MESH :
- chemical , genetics : Estrogen Receptor alpha, Receptor, ErbB-2.
- chemical , metabolism : Estrogen Receptor alpha, RNA, Messenger, Receptor, ErbB-2.
- chemical , therapeutic use : Antineoplastic Agents, Trastuzumab.
- drug therapy : Breast Neoplasms, Carcinoma.
- metabolism : Breast Neoplasms, Carcinoma.
- Adult, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic.
Abstract
A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, butreferred to asHER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of this is unknown.
DOI: 10.1001/jamaoncol.2016.0339
PubMed: 27100299
Affiliations:
- Allemagne, Australie, Belgique, France, Grèce, Italie, Royaume-Uni, États-Unis
- Angleterre, Attique (région), Dakota du Sud, District de Kassel, Hesse (Land), Illinois, Lombardie, Région de Bruxelles-Capitale
- Athènes, Bruxelles, Cassel (Hesse), Milan
- Université libre de Bruxelles
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B46
- to stream PubMed, to step Curation: 001B22
- to stream PubMed, to step Checkpoint: 001B22
- to stream Ncbi, to step Merge: 003444
- to stream Ncbi, to step Curation: 003444
- to stream Ncbi, to step Checkpoint: 003444
- to stream Main, to step Merge: 002024
- to stream Main, to step Curation: 002025
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.</title><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Dafni, Urania" sort="Dafni, Urania" uniqKey="Dafni U" first="Urania" last="Dafni">Urania Dafni</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Karlis, Dimitris" sort="Karlis, Dimitris" uniqKey="Karlis D" first="Dimitris" last="Karlis">Dimitris Karlis</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Polydoropoulou, Varvara" sort="Polydoropoulou, Varvara" uniqKey="Polydoropoulou V" first="Varvara" last="Polydoropoulou">Varvara Polydoropoulou</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Young, Brandon M" sort="Young, Brandon M" uniqKey="Young B" first="Brandon M" last="Young">Brandon M. Young</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author><author><name sortKey="Willis, Scooter" sort="Willis, Scooter" uniqKey="Willis S" first="Scooter" last="Willis">Scooter Willis</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author><author><name sortKey="Long, Bradley" sort="Long, Bradley" uniqKey="Long B" first="Bradley" last="Long">Bradley Long</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of Chicago, Chicago, Illinois.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Pathology, University of Chicago, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="De Azambuja, Evandro" sort="De Azambuja, Evandro" uniqKey="De Azambuja E" first="Evandro" last="De Azambuja">Evandro De Azambuja</name><affiliation wicri:level="4"><nlm:affiliation>BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Sotiriou, Christos" sort="Sotiriou, Christos" uniqKey="Sotiriou C" first="Christos" last="Sotiriou">Christos Sotiriou</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation wicri:level="3"><nlm:affiliation>University of Milan, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Milan, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name><affiliation wicri:level="3"><nlm:affiliation>Targos Molecular Pathology GmbH, Kassel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Targos Molecular Pathology GmbH, Kassel</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="2"><nlm:affiliation>Royal Marsden Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Royal Marsden Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Leyland Jones, Brian" sort="Leyland Jones, Brian" uniqKey="Leyland Jones B" first="Brian" last="Leyland-Jones">Brian Leyland-Jones</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27100299</idno><idno type="pmid">27100299</idno><idno type="doi">10.1001/jamaoncol.2016.0339</idno><idno type="wicri:Area/PubMed/Corpus">001B46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B46</idno><idno type="wicri:Area/PubMed/Curation">001B22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B22</idno><idno type="wicri:Area/PubMed/Checkpoint">001B22</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B22</idno><idno type="wicri:Area/Ncbi/Merge">003444</idno><idno type="wicri:Area/Ncbi/Curation">003444</idno><idno type="wicri:Area/Ncbi/Checkpoint">003444</idno><idno type="wicri:Area/Main/Merge">002024</idno><idno type="wicri:Area/Main/Curation">002025</idno><idno type="wicri:Area/Main/Exploration">002025</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.</title><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Dafni, Urania" sort="Dafni, Urania" uniqKey="Dafni U" first="Urania" last="Dafni">Urania Dafni</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Karlis, Dimitris" sort="Karlis, Dimitris" uniqKey="Karlis D" first="Dimitris" last="Karlis">Dimitris Karlis</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Polydoropoulou, Varvara" sort="Polydoropoulou, Varvara" uniqKey="Polydoropoulou V" first="Varvara" last="Polydoropoulou">Varvara Polydoropoulou</name><affiliation wicri:level="3"><nlm:affiliation>Frontier Science Foundation- Hellas, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Frontier Science Foundation- Hellas, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Young, Brandon M" sort="Young, Brandon M" uniqKey="Young B" first="Brandon M" last="Young">Brandon M. Young</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author><author><name sortKey="Willis, Scooter" sort="Willis, Scooter" uniqKey="Willis S" first="Scooter" last="Willis">Scooter Willis</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author><author><name sortKey="Long, Bradley" sort="Long, Bradley" uniqKey="Long B" first="Bradley" last="Long">Bradley Long</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of Chicago, Chicago, Illinois.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Pathology, University of Chicago, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="De Azambuja, Evandro" sort="De Azambuja, Evandro" uniqKey="De Azambuja E" first="Evandro" last="De Azambuja">Evandro De Azambuja</name><affiliation wicri:level="4"><nlm:affiliation>BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Sotiriou, Christos" sort="Sotiriou, Christos" uniqKey="Sotiriou C" first="Christos" last="Sotiriou">Christos Sotiriou</name><affiliation wicri:level="4"><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation wicri:level="3"><nlm:affiliation>University of Milan, European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Milan, European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name><affiliation wicri:level="3"><nlm:affiliation>Targos Molecular Pathology GmbH, Kassel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Targos Molecular Pathology GmbH, Kassel</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="2"><nlm:affiliation>Royal Marsden Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Royal Marsden Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Leyland Jones, Brian" sort="Leyland Jones, Brian" uniqKey="Leyland Jones B" first="Brian" last="Leyland-Jones">Brian Leyland-Jones</name><affiliation wicri:level="2"><nlm:affiliation>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Dakota du Sud</region></placeName><wicri:cityArea>Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls</wicri:cityArea></affiliation></author></analytic><series><title level="j">JAMA oncology</title><idno type="eISSN">2374-2445</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antineoplastic Agents (therapeutic use)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (metabolism)</term><term>Carcinoma (drug therapy)</term><term>Carcinoma (metabolism)</term><term>Chemotherapy, Adjuvant</term><term>Disease-Free Survival</term><term>Estrogen Receptor alpha (genetics)</term><term>Estrogen Receptor alpha (metabolism)</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>In Situ Hybridization, Fluorescence</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>RNA, Messenger (metabolism)</term><term>Randomized Controlled Trials as Topic</term><term>Receptor, ErbB-2 (genetics)</term><term>Receptor, ErbB-2 (metabolism)</term><term>Trastuzumab (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (métabolisme)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse multivariée</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Carcinomes (métabolisme)</term><term>Carcinomes (traitement médicamenteux)</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Immunohistochimie</term><term>Modèles de hasards proportionnels</term><term>Pronostic</term><term>Récepteur ErbB-2 (génétique)</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Récepteur alpha des oestrogènes (génétique)</term><term>Récepteur alpha des oestrogènes (métabolisme)</term><term>Survie sans rechute</term><term>Technique FISH</term><term>Traitement médicamenteux adjuvant</term><term>Trastuzumab (usage thérapeutique)</term><term>Tumeurs du sein (métabolisme)</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Estrogen Receptor alpha</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Estrogen Receptor alpha</term><term>RNA, Messenger</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Récepteur ErbB-2</term><term>Récepteur alpha des oestrogènes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN messager</term><term>Carcinomes</term><term>Récepteur ErbB-2</term><term>Récepteur alpha des oestrogènes</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinomes</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chemotherapy, Adjuvant</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>In Situ Hybridization, Fluorescence</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse multivariée</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Immunohistochimie</term><term>Modèles de hasards proportionnels</term><term>Pronostic</term><term>Survie sans rechute</term><term>Technique FISH</term><term>Traitement médicamenteux adjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, butreferred to asHER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of this is unknown.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Grèce</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Attique (région)</li><li>Dakota du Sud</li><li>District de Kassel</li><li>Hesse (Land)</li><li>Illinois</li><li>Lombardie</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Athènes</li><li>Bruxelles</li><li>Cassel (Hesse)</li><li>Milan</li></settlement><orgName><li>Université libre de Bruxelles</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></noRegion></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Dafni, Urania" sort="Dafni, Urania" uniqKey="Dafni U" first="Urania" last="Dafni">Urania Dafni</name></region><name sortKey="Karlis, Dimitris" sort="Karlis, Dimitris" uniqKey="Karlis D" first="Dimitris" last="Karlis">Dimitris Karlis</name><name sortKey="Polydoropoulou, Varvara" sort="Polydoropoulou, Varvara" uniqKey="Polydoropoulou V" first="Varvara" last="Polydoropoulou">Varvara Polydoropoulou</name></country><country name="États-Unis"><region name="Dakota du Sud"><name sortKey="Young, Brandon M" sort="Young, Brandon M" uniqKey="Young B" first="Brandon M" last="Young">Brandon M. Young</name></region><name sortKey="Leyland Jones, Brian" sort="Leyland Jones, Brian" uniqKey="Leyland Jones B" first="Brian" last="Leyland-Jones">Brian Leyland-Jones</name><name sortKey="Long, Bradley" sort="Long, Bradley" uniqKey="Long B" first="Bradley" last="Long">Bradley Long</name><name sortKey="Willis, Scooter" sort="Willis, Scooter" uniqKey="Willis S" first="Scooter" last="Willis">Scooter Willis</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="De Azambuja, Evandro" sort="De Azambuja, Evandro" uniqKey="De Azambuja E" first="Evandro" last="De Azambuja">Evandro De Azambuja</name></region><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name><name sortKey="Sotiriou, Christos" sort="Sotiriou, Christos" uniqKey="Sotiriou C" first="Christos" last="Sotiriou">Christos Sotiriou</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name></region></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name></region></country><country name="France"><noRegion><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002025 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002025 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27100299
|texte= Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27100299" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |